Alternative drug delivery approaches for the therapy of inflammatory bowel disease.

This article shall give an overview on drug delivery systems for new therapeutic strategies in the treatment of inflammatory bowel disease. The various features of the different approaches allowing locally restricted drug delivery to the inflamed colon are discussed including the main physiological and pathophysiological limitations for the different systems. Conventional drug delivery systems are tightly adapted from developments for colonic delivery by oral administration triggered by release mechanisms owing to the physiological environment that these systems encounter in the colonic region. The newer developments in this context aim for an increased selectivity of drug delivery by targeting mechanisms which have a closer relation to pathophysiological particularities of the disease. Therefore, we were focused especially on new strategies for such treatment including liposomal formulations, cyclodextrins, micro- or nanoparticles, viral gene therapy approaches, and others. Effective and selective delivery even of an otherwise nonspecifically acting drug could provide new therapeutic pathways in the treatment of inflammatory bowel disease.

[1]  A. Lamprecht,et al.  Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. Lamprecht,et al.  Low molecular weight heparin loaded pH-sensitive microparticles. , 2007, International journal of pharmaceutics.

[3]  A. Ciccodicola,et al.  Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine‐loaded liposomes , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  P. Lakatos.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.

[5]  A. Lamprecht,et al.  Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. , 2006, International journal of pharmaceutics.

[6]  Y. Barenholz,et al.  Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD , 2006, Journal of drug targeting.

[7]  Y. Kawashima,et al.  Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.

[8]  D. Fleisher,et al.  Liposomal Formulations of Inflammatory Bowel Disease Drugs: Local versus Systemic Drug Delivery in a Rat Model , 2005, Pharmaceutical Research.

[9]  Y. Kawashima,et al.  A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[10]  J. Hanes,et al.  Enhanced adhesion of ligand‐conjugated biodegradable particles to colitic venules , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  D. Friend.  New oral delivery systems for treatment of inflammatory bowel disease. , 2005, Advanced drug delivery reviews.

[12]  U. Klotz,et al.  Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. , 2005, Advanced drug delivery reviews.

[13]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[14]  B. Pan,et al.  Drug therapy for ulcerative colitis , 2004 .

[15]  C. Lehr,et al.  Lectin-mediated drug targeting: history and applications. , 2004, Advanced drug delivery reviews.

[16]  Y. Barenholz,et al.  Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes , 2004, Pharmaceutical Research.

[17]  Aliasger K Salem,et al.  Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Kelleher,et al.  Glucocorticoid resistance in inflammatory bowel disease. , 2003, The Journal of endocrinology.

[19]  Julie S. Jurenka,et al.  Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. , 2003, Alternative medicine review : a journal of clinical therapeutic.

[20]  R. Farrell.  Epidermal growth factor for ulcerative colitis. , 2003, The New England journal of medicine.

[21]  A. Lamprecht.  Multiparticulate systems in the treatment of inflammatory bowel disease. , 2003, Current drug targets. Inflammation and allergy.

[22]  M. Neurath,et al.  Gene transfer approaches for the treatment of inflammatory bowel disease , 2003, Gene Therapy.

[23]  H. Ogata,et al.  Cytokine and anti-cytokine therapies for inflammatory bowel disease. , 2003, Current pharmaceutical design.

[24]  S. Watson,et al.  Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. , 2003, The American journal of pathology.

[25]  R. Wiwattanapatapee,et al.  Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[26]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[27]  W. Sandborn.  Strategies for targeting tumour necrosis factor in IBD. , 2003, Best practice & research. Clinical gastroenterology.

[28]  G. Porro,et al.  Inflammatory bowel disease: new insights into pathogenesis and treatment , 2002, Journal of internal medicine.

[29]  L. Steidler.  In situ delivery of cytokines by genetically engineered Lactococcus lactis , 2002, Antonie van Leeuwenhoek.

[30]  T. Kirkegaard,et al.  Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease , 2002 .

[31]  Massimo Campieri.  New steroids and new salicylates in inflammatory bowel disease: a critical appraisal , 2002, Gut.

[32]  Y. Tabata,et al.  New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. , 2002, The Journal of pharmacology and experimental therapeutics.

[33]  D. Vestweber,et al.  Leukocyte rolling is exclusively mediated by P‐selectinin colonic venules , 2002, British journal of pharmacology.

[34]  Libo Yang,et al.  Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. , 2002, International journal of pharmaceutics.

[35]  M. Regueiro,et al.  Medical therapy for ulcerative colitis. , 2002, Gastroenterology clinics of North America.

[36]  B. Goins,et al.  Accumulation of PEG-liposomes in the Inflamed Colon of Rats: Potential for Therapeutic and Diagnostic Targeting of Inflammatory Bowel Diseases , 2002, Journal of drug targeting.

[37]  M. Neurath,et al.  Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA1 , 2002, The Journal of Immunology.

[38]  F. Hirayama,et al.  Prednisolone‐appended α‐cyclodextrin: Alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6‐trinitrobenzenesulfonic acid‐induced colitis rats , 2001 .

[39]  Y. Kawashima,et al.  Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  Y. Jeong,et al.  Application of Eudragit P‐4135F for the delivery of ellagic acid to the rat lower small intestine , 2001, The Journal of pharmacy and pharmacology.

[41]  Claus-Michael Lehr,et al.  Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa , 2001, Pharmaceutical Research.

[42]  Y. Ikada,et al.  An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. , 2001, The Journal of pharmacology and experimental therapeutics.

[43]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[44]  V. Sinha,et al.  Colonic Drug Delivery: Prodrug Approach , 2001, Pharmaceutical Research.

[45]  S. Yamaoka,et al.  Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB* , 2001, The Journal of Biological Chemistry.

[46]  T. Beckert,et al.  A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. , 2001, International journal of pharmaceutics.

[47]  K. Takada,et al.  Colon Delivery Efficiencies of Intestinal Pressure‐controlled Colon Delivery Capsules Prepared by a Coating Machine in Human Subjects , 2000, The Journal of pharmacy and pharmacology.

[48]  P. Bass,et al.  The Effect of Local Attachment of Cationized Antioxidant Enzymes on Experimental Colitis in the Rat , 2000, Pharmaceutical Research.

[49]  B. Sands.  Medical therapy of steroid-resistant Crohn's disease. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[50]  R. Giacomelli,et al.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis , 2000, Gut.

[51]  W. Reinisch,et al.  Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. , 2000, Human gene therapy.

[52]  W. Strober,et al.  Treatment of Experimental (Trinitrobenzene Sulfonic Acid) Colitis by Intranasal Administration of Transforming Growth Factor (Tgf)-β1 Plasmid , 2000, The Journal of Experimental Medicine.

[53]  C. Hogaboam,et al.  Interleukin 10 gene transfer prevents experimental colitis in rats , 2000, Gut.

[54]  P. Keeling,et al.  High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. , 2000, Gastroenterology.

[55]  W. Oyen,et al.  Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG. , 1999, Annals of surgery.

[56]  C. Sempoux,et al.  CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. , 1999, Life sciences.

[57]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[58]  Press,et al.  Gastrointestinal pH profiles in patients with inflammatory bowel disease , 1998, Alimentary pharmacology & therapeutics.

[59]  M. Alonso,et al.  Design of microencapsulated chitosan microspheres for colonic drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[60]  C. Samyn,et al.  Use of azo polymers for colon-specific drug delivery. , 1997, Journal of pharmaceutical sciences.

[61]  F. Graham,et al.  Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. , 1997, The Journal of clinical investigation.

[62]  W. Oyen,et al.  Scintigraphic evaluation of experimental colitis in rabbits. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  Y. Ikada,et al.  Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. , 1996, Vaccine.

[64]  I. Bjarnason,et al.  Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. , 1996, Gut.

[65]  C. Neut,et al.  Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease , 1995, Digestive Diseases and Sciences.

[66]  T. Macdonald,et al.  Aetiology and pathogenesis of chronic inflammatory bowel disease. , 1994, Bailliere's clinical gastroenterology.

[67]  Clive G. Wilson,et al.  The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis , 1992 .

[68]  I. Mena,et al.  Colonic motility and transit in health and ulcerative colitis. , 1991, Gastroenterology.

[69]  R. Russell,et al.  Comparison of different measurements of intestinal permeability in inflammatory bowel disease. , 1991, The American journal of gastroenterology.

[70]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[71]  C. Seldenrijk,et al.  Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease. , 1989, Gut.

[72]  J. Rhodes,et al.  Altered lectin binding by colonic epithelial glycoconjugates in ulcerative colitis and Crohn's disease , 1988, Digestive Diseases and Sciences.

[73]  A. Dhillon,et al.  Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. , 1988, Gut.

[74]  S. Davis,et al.  Transit of pharmaceutical dosage forms through the small intestine. , 1986, Gut.

[75]  J. Hardy,et al.  Drug delivery to the proximal colon , 1985, The Journal of pharmacy and pharmacology.

[76]  A. Onderdonk,et al.  A polymeric drug for treatment of inflammatory bowel disease. , 1983, Journal of medicinal chemistry.

[77]  J. H. Baron,et al.  Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide , 1983, Digestive Diseases and Sciences.

[78]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[79]  G. Mooter.  Colon drug delivery , 2006 .

[80]  W. Sandborn.  New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. , 2005, Reviews in gastroenterological disorders.

[81]  M. K. Chourasia,et al.  Pharmaceutical approaches to colon targeted drug delivery systems. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[82]  Y. Kawashima,et al.  Carrier systems for the treatment of inflammatory bowel disease , 2002 .

[83]  T. Dassopoulos,et al.  Evolving treatment strategies for inflammatory bowel disease. , 2001, Annual review of medicine.

[84]  Y. Ikada,et al.  Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. , 2000, The Journal of pharmacology and experimental therapeutics.

[85]  J. Woodley.  Lectins for gastrointestinal targeting--15 years on. , 2000, Journal of drug targeting.

[86]  M. Peppercorn,et al.  Promising New Agents for the Treatment of Inflammatory Bowel Disorders , 1999, Drugs in R&D.

[87]  E. Mazzon,et al.  Experimental colitis increases small intestine permeability in the rat. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[88]  M. Alonso,et al.  Development of new chitosan-cellulose multicore microparticles for controlled drug delivery. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[89]  K. Barrett,et al.  Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. , 1998, The American journal of physiology.

[90]  H. Brøndsted,et al.  Current applications of polysaccharides in colon targeting. , 1996, Critical reviews in therapeutic drug carrier systems.

[91]  A. Rubinstein.  Approaches and opportunities in colon-specific drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[92]  J. Fell,et al.  Targeting drugs to the colon: delivery systems for oral administration. , 1994, Journal of drug targeting.

[93]  Eastwood Ma.  Colonic diverticulosis: medical and dietary management. , 1975 .